Latest News and Press Releases

Yaqrit presents phase 2a data at EASL on oral HE prevention treatment; and an improved HE patient staging tool approved for use by FDA in HE phase 3

Yaqrit announces eight upcoming presentations at the EASL Congress showcasing progress for drugs and devices in late stage trials in advanced liver disease

Yaqrit strengthens board and senior management with seasoned industry leaders. Poised to implement late stage clinical strategy in advanced liver disease.

New York, United States , May 25, 2023 (GLOBE NEWSWIRE) -- The Global Overt Hepatic Encephalopathy Market Size is to grow from USD 180.2 million in 2022 to USD 397.5 million by 2032, at a Compound...

NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is pleased to announce the completion of a share exchange...

-- Mallinckrodt to commence cash tender offer to purchase Ocera Therapeutics for $1.52 per share, plus Contingent Value Right -- -- Hepatic encephalopathy (HE) is a neuropsychiatric syndrome...

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that clinical study findings of OCR-002 (ornithine...

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that four abstracts related to clinical study...

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on the development...

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., June 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced the dosing of the first patients in Part Two of a...